Literature DB >> 7259927

Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man.

V Facchini, J A Timbrell.   

Abstract

1 The 0-24 h urine from hypertensive patients treated with hydralazine (100 mg twice daily) has been analysed by gas chromatography and high pressure liquid chromatography. 2 4-N-Acetylhydrazinophthalazine-1-one (NAcHPZ), s-triazolo [3, 4-a] phthalazine (TP), phthalazinone (PZ) and hydralazine (free, H; acid-labile hydrazones, HH) were detected and assayed. 3 The results indicate that slow acetylators excrete less NAcHPZ and TP than rapid acetylators but more PZ and HH. 4 Free hydralazine was present in low levels and was only detected in some urine samples. 5 The ratios of the metabolites NAcHPZ/HH; TP/HH; NAcHPZ/PZ and PZ/TP are different in the two acetylator phenotypes. 6 It is possible the ratio PZ/TP may be used for determination of acetylator phenotype. 7 It is concluded that hydralazine metabolism is dependent on the acetylator phenotype.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7259927      PMCID: PMC1401654          DOI: 10.1111/j.1365-2125.1981.tb01131.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  THE METABOLISM OF 1-HYDRAZINOPHTHALAZINE.

Authors:  W M MCISAAC; M KANDA
Journal:  J Pharmacol Exp Ther       Date:  1964-01       Impact factor: 4.030

2.  Determination of hydralazine in tablets by gas chromatography.

Authors:  K M Smith; R N Johnson; B T Kho
Journal:  J Chromatogr       Date:  1977-07-21

Review 3.  Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.

Authors:  H M Perry
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

4.  Identification of two new metabolites of hydralazine from human urine.

Authors:  S B Zak; T G Gilleran; J Karliner; G Lukas
Journal:  J Med Chem       Date:  1974-03       Impact factor: 7.446

5.  An improved and simplified method of detecting the acetylator phenotype.

Authors:  D A Evans
Journal:  J Med Genet       Date:  1969-12       Impact factor: 6.318

6.  A major metabolite of 1-hydrazinophthalazine.

Authors:  H Zimmer; J McManus; T Novinson; E V Hess; A H Litwin
Journal:  Arzneimittelforschung       Date:  1970-10

7.  Determination of hydralazine and its acetylated metabolites in urine by gas chromatography and high-pressure liquid chromatography.

Authors:  V Facchini; A J Streeter; J A Timbrell
Journal:  J Chromatogr       Date:  1980-01-04

8.  The comeback of hydralazine.

Authors:  J Koch-Weser
Journal:  Am Heart J       Date:  1978-01       Impact factor: 4.749

9.  Determination of hydralazine metabolites: 4-hydrazino-phthalazin-1-one and n-acetylhydrazinophthalazin-1-one by gas chromatography and s-triazolo[3,4-alpha]phthalazine and phthalazinone by high-performance liquid chromatography.

Authors:  V Facchini; J A Timbrell
Journal:  J Chromatogr       Date:  1980-08-08

10.  Polymorphic acetylation of hydralazine.

Authors:  J A Timbrell; S J Harland; V Facchini
Journal:  Clin Pharmacol Ther       Date:  1980-09       Impact factor: 6.875

View more
  6 in total

Review 1.  Drug-related lupus. Incidence, mechanisms and clinical implications.

Authors:  L E Adams; E V Hess
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

Review 2.  Genotype-Guided Hydralazine Therapy.

Authors:  Kimberly S Collins; Anthony L J Raviele; Amanda L Elchynski; Alexander M Woodcock; Yang Zhao; Rhonda M Cooper-DeHoff; Michael T Eadon
Journal:  Am J Nephrol       Date:  2020-09-14       Impact factor: 3.754

3.  Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period.

Authors:  W A Bogers; L Meems
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Hydralazine-induced lupus: is there a toxic metabolic pathway?

Authors:  J A Timbrell; V Facchini; S J Harland; R Mansilla-Tinoco
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Evaluation of once daily endralazine in hypertension.

Authors:  R Wu; J D Spence; S G Carruthers
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 6.  Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.

Authors:  David W Hein; Lori M Millner
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-11-03       Impact factor: 4.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.